CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
Tóm tắt
Ovarian cancer is the most-deadly gynecologic malignancy, with greater than 14,000 women expected to succumb to the disease this year in the United States alone. In the front-line setting, patients are treated with a platinum and taxane doublet. Although 40–60% of patients achieve complete clinical response to first-line chemotherapy, 25% are inherently platinum-resistant or refractory with a median overall survival of about one year. More than 80% of women afflicted with ovarian cancer will recur. Many attempts have been made to understand the mechanism of platinum and taxane based chemotherapy resistance. However, despite decades of research, few predictive markers of chemotherapy resistance have been identified. Here, we review the current understanding of one of the most common genetic alterations in epithelial ovarian cancer, CCNE1 (cyclin E1) amplification, and its role as a potential predictive marker of cytotoxic chemotherapy resistance. CCNE1 amplification has been identified as a primary oncogenic driver in a subset of high grade serous ovarian cancer that have an unmet clinical need. Understanding the interplay between cyclin E1 amplification and other common ovarian cancer genetic alterations provides the basis for chemotherapeutic resistance in CCNE1 amplified disease. Exploration of the effect of cyclin E1 amplification on the cellular machinery that causes dysregulated proliferation in cancer cells has allowed investigators to explore promising targeted therapies that provide the basis for emerging clinical trials.
Từ khóa
Tài liệu tham khảo
Chi, D., Berchuck, A., Dizon, D., and Yashar, C. (2017). Chapter 23—Epithelial Ovarian Cancer. Principles and Practice of Gynecologic Oncology, Wolters Kluwer. [7th ed.].
McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101
National Comprehensive Cancer Network (2018). Ovarian cancer: Including fallopian tube cancer and primary peritoneal cancer. NCCN Clin. Pract. Guid. Oncol., 1, 1–115.
Davis, 2014, “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?, Gynecol. Oncol., 133, 624, 10.1016/j.ygyno.2014.02.038
Evans, 1983, Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division, Cell, 33, 389, 10.1016/0092-8674(83)90420-8
The Nobel Prize in Physiology or Medicine 2001 (2020, January 20). The Nobel Foundation. Available online: https://www.nobelprize.org/prizes/medicine/2001/summary/.
“The Life Scientific” BBC Radio 4 (2020, January 20). British Broadcasting Corportaion. Available online: https://www.bbc.co.uk/programmes/b0184rfy#synopsis.
Koff, 1991, Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family, Cell, 66, 1217, 10.1016/0092-8674(91)90044-Y
Lew, 1991, Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast, Cell, 66, 1197, 10.1016/0092-8674(91)90042-W
Murray, 2004, Recycling the cell cycle: Cyclins revisited, Cell, 116, 221, 10.1016/S0092-8674(03)01080-8
Koff, 1992, Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle, Science, 257, 1689, 10.1126/science.1388288
Sears, 2002, Signaling networks that link cell proliferation and cell fate, J. Biol. Chem., 277, 11617, 10.1074/jbc.R100063200
Stevaux, 2002, A revised picture of the E2F transcriptional network and RB function, Curr. Opin. Cell Biol., 14, 684, 10.1016/S0955-0674(02)00388-5
Coller, 2000, Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion, Proc. Natl. Acad. Sci. USA, 97, 3260, 10.1073/pnas.97.7.3260
Grant, 2017, The Temporal Regulation of S Phase Proteins During G1, Adv. Exp. Med. Biol., 1042, 335, 10.1007/978-981-10-6955-0_16
Coverley, 2002, Distinct roles for cyclins E and A during DNA replication complex assembly and activation, Nat. Cell Biol., 4, 523, 10.1038/ncb813
Fisher, 2011, Control of DNA replication by cyclin-dependent kinases in development, Results Probl. Cell Differ., 53, 201, 10.1007/978-3-642-19065-0_10
Ramirez, 1998, Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A, Nature, 396, 184, 10.1038/24190
Caldon, 2010, Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer, Cell Div., 5, 2, 10.1186/1747-1028-5-2
Yu, 2017, CBX7 is a glioma prognostic marker and induces G1/S arrest via the silencing of CCNE1, Oncotarget, 8, 26637, 10.18632/oncotarget.15789
Forzati, 2012, CBX7 is a tumor suppressor in mice and humans, J. Clin. Investig., 122, 612, 10.1172/JCI58620
Wang, 2019, MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells, Anticancer Drugs, 30, 81, 10.1097/CAD.0000000000000700
Xia, 2009, MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells, Biochem. Biophys. Res. Commun., 380, 205, 10.1016/j.bbrc.2008.12.169
Liu, 2008, miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes, Nucleic Acids Res., 36, 5391, 10.1093/nar/gkn522
Singer, 1999, Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells, Genes Dev., 13, 2375, 10.1101/gad.13.18.2375
Bhaskaran, 2012, Fbw7α and Fbw7γ Collaborate to Shuttle Cyclin E1 into the Nucleolus for Multiubiquitylation, Mol. Cell. Biol., 33, 85, 10.1128/MCB.00288-12
Cancer Genome Atlas Research Network TCGA (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609–615.
Cerami, 2012, The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data, Cancer Discov., 2, 401, 10.1158/2159-8290.CD-12-0095
Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, 1, 10.1126/scisignal.2004088
Biernacka, 2010, Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification, Cancer Res., 70, 5074, 10.1158/0008-5472.CAN-09-4094
Brown, 2017, Targeting DNA Repair in Cancer: Beyond PARP Inhibitors, Cancer Discov., 7, 20, 10.1158/2159-8290.CD-16-0860
Kawamur, 2004, Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression, Cancer Res., 64, 4800, 10.1158/0008-5472.CAN-03-3908
Hanashiro, 2008, Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells, Oncogene, 27, 5288, 10.1038/onc.2008.161
Davidson, 2007, Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma, Cancer, 110, 1264, 10.1002/cncr.22918
Hwang, 2005, Cyclin E in normal and neoplastic cell cycles, Oncogene, 24, 2776, 10.1038/sj.onc.1208613
Muggia, 2014, ‘BRCAness’ and its implications for platinum action in gynecologic cancer, Anticancer Res., 34, 551
Scott, 2015, Poly (ADP-ribose) polymerase inhibitors: Recent advances and future development, J. Clin. Oncol., 33, 1397, 10.1200/JCO.2014.58.8848
Burgess, 2018, Defective DNA repair in hereditary ovarian cancers: Implications for therapy, Am. J. Health Syst. Pharm., 75, 1697, 10.2146/ajhp180124
Rocha, C.R.R., Silva, M.M., Quinet, A., Cabral-Neto, J.B., and Menck, C.F.M. (2018). DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo), 73.
Martin, 2008, Platinum resistance: The role of DNA repair pathways, Clin. Cancer Res., 14, 1291, 10.1158/1078-0432.CCR-07-2238
Jordan, 1996, Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death, Cancer Res., 56, 816
Brito, 2006, Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint, Curr. Biol., 16, 1194, 10.1016/j.cub.2006.04.043
Raab, 2020, Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1, Int. J. Cancer, 146, 1086, 10.1002/ijc.32559
Biernacka, 2010, Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C, Cancer Res., 70, 5085, 10.1158/0008-5472.CAN-09-4095
Nakayama, 2010, Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer, Cancer, 116, 2621, 10.1002/cncr.24987
Yuan, 2018, Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers, Cancer Cell, 34, 549, 10.1016/j.ccell.2018.08.019
Etemadmoghadam, 2009, Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas, Clin. Cancer Res., 15, 1417, 10.1158/1078-0432.CCR-08-1564
Sapoznik, 2017, CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance, Oncotarget, 8, 62240, 10.18632/oncotarget.19272
Jia, Y., Chen, L., Jia, Q., Dou, X., Xu, N., and Liao, D.J. (2016). The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption. J. Carcinog., 15.
Turner, 2019, Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer, J. Clin. Oncol., 37, 1169, 10.1200/JCO.18.00925
Josefsberg Ben-Yehoshua, L., Beider, K., Shimoni, A., Ostrovsky, O., Samookh, M., Peled, A., and Nagler, A. (2012). Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS ONE, 7.
Kim, 2016, Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines, Investig. Clin. Urol., 57, 63, 10.4111/icu.2016.57.1.63
Tadesse, 2019, Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update, J. Med. Chem., 62, 4233, 10.1021/acs.jmedchem.8b01469
Yang, 2015, Cyclin-dependent Kinase 2 is an Ideal Target for Ovary Tumors with Elevated Cyclin E1 Expression, Oncotarget, 6, 20801, 10.18632/oncotarget.4600
Etemadmoghadam, 2013, Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer, Clin. Cancer Res., 19, 60, 10.1158/1078-0432.CCR-13-1337
Asghar, 2015, The history and future of targeting cyclin-dependent kinases in cancer therapy, Nat. Rev. Drug Discov., 14, 130, 10.1038/nrd4504
Beale, 2016, Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer, Br. J. Cancer., 115, 682, 10.1038/bjc.2016.238
Rao, 2017, Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer, Oncotarget, 8, 83925, 10.18632/oncotarget.20202
Beck, 2012, Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption, Mol. Cell Biol., 32, 4226, 10.1128/MCB.00412-12
Marcus, 2019, FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors, Clin. Cancer Res., 25, 3753, 10.1158/1078-0432.CCR-18-4070
2019, A paradigm shift in biomarker guided oncology drug development, Ann. Transl. Med., 7, 148, 10.21037/atm.2019.03.36
Noack, 2018, Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics, Oncotarget, 9, 25842, 10.18632/oncotarget.25386
Takada, 2017, FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A, Cancer Res., 77, 4881, 10.1158/0008-5472.CAN-17-1240